Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Liquidia Corporation (LQDA:NASDAQ), powered by AI.
Liquidia Corporation is currently trading at $71.23. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Liquidia Corporation on Alpha Lenz.
View Liquidia Corporation's valuation metrics on Alpha Lenz.
“Liquidia Corporation's ROE is -113.0%. Explore profitability and growth together.”
Ask for details →Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of innovative therapies. Primarily engaged in the healthcare sector, Liquidia employs PRINT technology, a proprietary particle engineering platform that allows precise drug delivery by designing uniform particles in multiple sizes, shapes, and compositions. This technological advancement enables them to optimize therapeutic outcomes by improving the safety and efficacy profiles of pharmaceutical products. The company's efforts are directed towards inhalation therapies to treat rare and serious conditions, significantly impacting respiratory care as well as other medical fields. Based in Research Triangle Park, North Carolina, Liquidia plays a crucial role in advancing healthcare solutions by addressing unmet medical needs with its innovative approaches. Drawing significant attention within the pharmaceutical and life sciences industries, the company represents a critical part of the ecosystem dedicated to enhancing patient care through technology-driven drug design.
“Liquidia Corporation's ROE is -113.0%. Explore profitability and growth together.”
Ask for details →Liquidia Corporation (ticker: LQDA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 170 employees.
The current price is $71.23 with a P/E ratio of -x and P/B of -x.
ROE is -112.97% and operating margin is -32.45%. Annual revenue is $158M.